Last-resort drug opens door for lung cancer patients with HER2 mutation
NCT ID NCT06761976
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This program offers an experimental oral medication, sevabertinib, to adults with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in relatively good health. The goal is to provide access when no standard options remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.